Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis

Annals of the American Thoracic Society
M S MuhlebachSTAR-CF Study Team

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) prevalence continues to increase in patients with cystic fibrosis (CF) in the United States, reaching 26.5% in 2012. Approximately 30% of strains are SCCmec (staphylococcal cassette chromosome mec) IV type, frequently USA300, which in the general population have different genotypic and phenotypic features than SCCmec II type. We hypothesized that risk factors for acquisition and outcomes in patients with CF differed for "health care-associated" (SCCmec II) versus "community-associated" (SCCmec IV) MRSA strains. To determine the role of SCCmec type and Panton-Valentine leukocidin (PVL), MRSA isolates from patients not more than 18 years old at seven CF centers were typed and the association of potential risk factors and subsequent clinical course was assessed, using data provided by the CF Patient Registry. Participants with chronic MRSA (295) had typeable isolates and clinical data; 205 (69.5%) had SCCmec II PVL(-), 39 (13.2%) had SCCmec IV PVL(-), and 51 (17.3%) had SCCmec IV PVL(+) strains. SCCmec IV, compared with SCCmec II, increased during the study period, 1996-2010 (P = 0.03). SCCmec II was associated with Pseudomonas aeruginosa-positive cultures and three or more clinic...Continue Reading

References

Feb 1, 1993·Pediatric Pulmonology·X WangB G Ferris
Apr 3, 1998·Pediatrics·P M FarrellE H Mischler
Jan 5, 1999·American Journal of Respiratory and Critical Care Medicine·J L HankinsonK B Fedan
Sep 6, 2003·Journal of Clinical Microbiology·Melissa B Miller, Peter H Gilligan
Oct 7, 2004·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Tim W R LeeJames M Littlewood
Dec 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John S FrancisJohn G Bartlett
May 1, 2007·Pediatric Pulmonology·Clement L RenUNKNOWN Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis
Aug 2, 2008·American Journal of Respiratory and Critical Care Medicine·Elliott C DasenbrookMichael P Boyle
Feb 20, 2009·Journal of Clinical Microbiology·Jennifer S GoodrichPeter H Gilligan
Mar 12, 2009·Current Molecular Medicine·Ruud H Deurenberg, Ellen E Stobberingh
Jun 6, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ari RobicsekLance R Peterson
Dec 8, 2009·Emerging Infectious Diseases·Eili KleinRamanan Laxminarayan
Feb 6, 2010·The Pediatric Infectious Disease Journal·Anne StoneLisa Saiman
Mar 9, 2010·Lancet·Frank R DeLeoHenry F Chambers
Jun 17, 2010·JAMA : the Journal of the American Medical Association·Elliott C DasenbrookMichael P Boyle
Dec 3, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ari RobicsekLance R Peterson
Mar 23, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Marianne S MuhlebachMelissa B Miller
Feb 11, 2012·The European Respiratory Journal·Joanne L FothergillCraig Winstanley
Jul 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lova SunRamanan Laxminarayan
Mar 19, 2013·International Journal of Medical Microbiology : IJMM·Anna C Shore, David C Coleman
Jun 15, 2013·Pediatric Pulmonology·E A ChampionUNKNOWN STAR-CF Study Team

❮ Previous
Next ❯

Citations

Feb 26, 2016·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·M C FirmidaA J Lopes
Dec 1, 2017·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Paula Pena AmayaMarta Mollerach
Aug 4, 2018·Pediatric Pulmonology·Nour Akil, Marianne S Muhlebach
May 10, 2018·The Pediatric Infectious Disease Journal·Nicholas M FuscoCalvin J Meaney
Aug 11, 2017·Current Opinion in Pulmonary Medicine·Marianne S Muhlebach
Oct 1, 2019·The Pediatric Infectious Disease Journal·Gabriela R OatesHector H Gutierrez
Jul 29, 2017·BMC Pulmonary Medicine·Kevin J PsoterMargaret Rosenfeld
Apr 24, 2019·Pediatric Pulmonology·Sachinkumar B SinghAnthony J Fischer
Jul 6, 2021·Pediatric Pulmonology·Harry S PorterfieldAnthony J Fischer

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

American Thoracic Association Journals

Discover the latest respiratory research published by the journals from the American Thoracic Society.